GBP/USD jumps to fresh weekly tops, 1.3600 mark back in sight
|- GBP/USD gained strong follow-through traction for the second straight session on Wednesday.
- The upbeat mood undermined the safe-haven USD and remained supportive of the momentum.
- Approval of COVID-19 vaccine by AstraZeneca/Oxford further boosted the global risk sentiment.
The USD selling remained unabated through the first half of the European session and pushed the GBP/USD pair to fresh weekly tops, around the 1.3575-80 region in the last hour.
The pair added to the previous day's goodish positive move and continued scaling higher for the second consecutive session on Wednesday. The momentum was exclusively sponsored by the heavily offered tone surrounding the US dollar and assisted the GBP/USD to reverse Monday's corrective slide.
Despite a Senate delay in US stimulus checks, investors remained optimistic about the likelihood of additional financial aid. This, along with increasing bets for a strong global economic recovery in 2021, remained supportive of the upbeat market mood and undermined the safe-haven greenback.
Investors' appetite for perceived riskier assets got an additional boost after UK regulators approved the use of the AstraZeneca/Oxford coronavirus vaccine. This was seen as another factor that drove some flows towards the British pound and remained supportive of the GBP/USD pair strong move up.
That said, concerns about the exclusion of the crucial services sector in Brexit agreement and a sharp rise in new cases infected by a mutant coronavirus in the UK might cap gains for the GBP/USD pair. Moreover, year-end thin liquidity might further hold bullish trades from placing fresh bets.
There isn't any major market-moving economic data due for release from the UK. The US economic docket features the second-tier releases of Goods Trade Balance, Chicago PMI and Pending Home Sales. This leaves the GBP/USD pair at the mercy of the USD price dynamics and the market risk sentiment.
Technical levels to watch
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.